ArticleBiology direct2026
LncRNA HNF1A-AS1 promotes prostate cancer progression via the miR-138-5p/KDM6B axis.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is a widespread malignancy with poor prognosis in advanced stages. However, the role of long non-coding RNA (lncRNA) HNF1A-AS1 in PCa progression and its underlying mechanisms remain largely unclear. This study aims to explore the expression trends and clinical associations of HNF1A-AS1 in PCa, and to reveal the potential functional networks by which it regulates the malignant progression of PCa.
methodsExpression of HNF1A-AS1 was detected in 113 pairs of PCa and adjacent tissues by quantitative real-time PCR (qRT-PCR). Cell Counting Kit-8 (CCK-8), Transwell, Western blot, and Fe²⁺ concentration assays were performed to assess cell proliferation, migration, invasion, and ferroptosis. Dual-luciferase reporter assays validated targeting relationships.
resultsHNF1A-AS1 was markedly upregulated in PCa tissues and cells. High expression of HNF1A-AS1 correlated with advanced tumor progression, poor differentiation, higher Gleason grade, and reduced recurrence-free survival. Silencing of HNF1A-AS1 suppressed PCa cell proliferation, migration, and invasion, and triggered biochemical events consistent with ferroptosis. Mechanistically, HNF1A-AS1 directly sponged miR-138-5p, which in turn targeted KDM6B. Rescue experiments confirmed that the HNF1A-AS1/miR-138-5p/KDM6B axis regulates malignant phenotypes and ferroptosis in PCa cells.
conclusionsHNF1A-AS1 represents a potential independent prognostic factor for PCa. HNF1A-AS1 drives PCa progression through suppression of ferroptosis via the miR-138-5p/KDM6B axis, representing a promising therapeutic candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.